Intervention Review

You have free access to this content

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

  1. Goran Hauser1,2,*,
  2. Tahany Awad2,
  3. Jesper Brok3,
  4. Kristian Thorlund4,
  5. Davor Štimac1,
  6. Mahasen Mabrouk5,
  7. Christian Gluud2,
  8. Lise Lotte Gluud6

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 28 FEB 2014

Assessed as up-to-date: 13 FEB 2014

DOI: 10.1002/14651858.CD005441.pub3


How to Cite

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD005441. DOI: 10.1002/14651858.CD005441.pub3.

Author Information

  1. 1

    Clinical Hospital Centre Rijeka, Department of Gastroenterology, Rijeka, Croatia

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, The Cochrane Hepato-Biliary Group, Copenhagen, Denmark

  3. 3

    Rigshospitalet, Paediatric Department 4072, Copenhagen, Denmark

  4. 4

    McMaster University, Department of Clinical Epidemiology and Biostatistics, Hamilton, Ontario, Canada

  5. 5

    Faculty of Medicine, Cairo University, Endemic Medicine and Liver Department, Cairo, Egypt

  6. 6

    Copenhagen University Hospital Hvidovre, Gastro Unit, Medical Division, Hvidovre, Denmark

*Goran Hauser, Department of Gastroenterology, Clinical Hospital Centre Rijeka, Kresimirova 42, Rijeka, 51 000, Croatia. ghauser@medri.hr.

Publication History

  1. Publication Status: New
  2. Published Online: 28 FEB 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Al-Faleh 2004 {published data only}
  • Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver International 2004;24:568-74.
Bruno 2004 {published data only}
  • Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. Journal of Hepatology 2004;41:474-81.
  • Bruno S, Camma C, Di Marco V, Rumi MG, Vinci M, Camozzi M, et al. Chronic hepatitis C (CH-C) genotype 1: an independent, multicenter RCT comparing PEG-IFN alfa-2b 12 kD plus ribavirin (RBV) and IFN alfa-2b plus RBV in naive patients. Journal of Hepatology 2003;38(Suppl 2):131-2.
Cariti 2002 {published data only}
  • Cariti G, Andreoni M, Calleri G, Manca A, Rosina F, Sartori M, et al. PEG-INF alpha-2A (40KD) plus ribavirin (RBV) vs IFN alpha-2A (ROFERON-A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]. Hepatology 2002;36(4 Pt 2):595A.
Derbala 2005 {published data only}
Derbala 2006 {published data only}
  • Derbala MF, Kaabi SR, Dweik NZ, Pasic F, Butt MT, Yakoob R, et al. Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage. World Journal of Gastroenterology 2006;12(35):5692-8.
Dollinger 2005 {published data only}
  • Dollinger MM, Dridi Y, Lesske J, Behl S, Fleig WE. Efficacy of daily consensus interferon and ribavirin compared to peg-interferon alpha-2B and interferon in non-responders with chronic hepatitis C [AASLD abstract]. Hepatology 2005;42(4 Suppl 1):691-2.
Esmat 2003 {published data only}
  • Esmat GH, Abouzied A, Abdel-Hamid M, Mohamed MK, Zalata K, El Raziky MS, et al. Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin [AASLD abstract]. Hepatology 2003;38(4 Suppl 1):314A-315A.
Fargion 2004 {published data only}
  • Fargion S, Borzio M, Cargnel A. End of treatment and sustained response to peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology 2003;38(4 Suppl 1):733A.
  • Fargion S, Borzio M, Cargnel A. Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC). Journal of Hepatology 2003;38(Suppl 2):139-40.
  • Fargion S, Borzio M, Cargnel A. Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology 2002;36(4 Pt 2):572A.
  • Fargion S, Borzio M, Maraschi A, Cargnel A. Sustained virological response (SVR) to peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC). Journal of Hepatology 2004;40(Suppl 1):140.
Fried 2002 {published data only}
  • Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernandez C, Dehesa-Violante M, Maldonado-Garza H, et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology 2003;2(3):135-9.
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002;347(13):975-82.
  • Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology 2004;40(4):675-81.
  • Hassanein TI, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al. Treatment with 40 kDa peginterferon alfa-2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin [AASLD abstract]. Hepatology 2001;34(4 Pt 2):243A.
  • Hassanein TI, Cooksley WGE, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al. QOL benefits observed as early as week 2 with peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV [EASL abstract]. Journal of Hepatology 2002;36(1):110.
  • Herrmann E, Lee J-H, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37(6):1351-8.
  • Lutchman G, Hoofnagle JH. Viral kinetics in hepatitis C. Hepatology 2003;37(6):1257-9.
  • Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004;22(4):257-65.
  • Sullivan SD, Green J, Patel KK, Craxi A, Alberti A, Giuliani G, et al. A comparison of cost-effectiveness of peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC). Journal of Hepatology 2003;38(Suppl 2):174-5.
  • Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. American Journal of Gastroenterology 2004;99:1490-6.
  • Zeuzem S, Herrmann E, Lee J-H, Marinos G, Modi M, Roth WK. Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]. Hepatology 2001;34(4 Pt 2):558A.
Hinrichsen 2002 {published data only}
  • Hinrichsen H, Buggisch P, Nasser S, Foelsch UR. A prospective randomised 24 week trial of peg-interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]. Hepatology 2002;36(4 Pt 2):311A.
Horsmans 2008 {published data only}
  • Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, et al. Weekly pegylated Interferon alpha-2b vs daily interferon a-2b versus standard regimen of Interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. Acto Gastro-Enterologica Belgica 2008;71(3):293-7.
Izumi 2004 {published data only}
  • Izumi N, Asahina Y, Kurosaki M, Uchihara M, Nishimura Y, Inoue K, et al. A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C. Intervirology 2004;47:102-7.
Lee 2005 {published data only}
Mangia 2005 {published data only}
  • Mangia A, Ricci GL, Persico M, Minerva N, Caretta V, Bacca D, et al. A randomized controlled trial of peginterferon alpha-2a (40 kD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C. Journal of Viral Hepatitis 2005;12(3):292-9.
Manns 2001 {published data only}
  • Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2003;17:687-94.
  • Condat B. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial. Hepato-Gastroenterology 2002;9(2):141-2.
  • Gish R, Bzowej N, Brooks L, Brass C, Weng W. Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C [AASLD abstract]. Hepatology 2002;36(4 Pt 2):582A.
  • Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clinical Pharmacology and Therapeutics 2002;72(4):349-61.
  • Manns MP, McHutchison JG, Gordon S, Rustgi V, Shiffman ML, Lee WM, et al. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]. Hepatology 2000;32(4 Pt 2):297A.
  • Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
  • McHutchison J, Manns M, Harvey J, Albrecht JK. Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg-interferon alfa-2b plus ribavirin [abstract]. Journal of Hepatology 2001;34(1):2-3.
  • McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123(4):1061-9.
  • McHutchison JG, Manns MP, Harvey J, Garaud J-J, Albrecht J. Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin. Hepatology 2001;34(4 Pt 2):417A.
  • McHutchison JG, Manns MP, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]. Hepatology 2001;34(4 Pt 2):329A.
  • Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated-interferon alpfa-2b and ribavirin combination [AASLD abstract]. Hepatology 2002;36(4 Pt 2):351A.
  • Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003;38(2):481-92.
  • Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38(1):75-85.
  • Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425-32.
  • Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK. Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. American Journal of Gastroenterology 2003;98(11):2354-62.
    Direct Link:
Napoli 2005 {published data only}
  • Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. New Microbiologica 2005;28:13-21.
Nevens 2010 {published data only}
  • Nevens F, Van Vlierberghe H, D'Heygere E, Delwaide J, Adler M, Henrion J, et al. A randomised, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Acta Gastroenterologica Belgica 2010;73:223-8.
PRETTY 2005 {published data only}
  • Mangia A, Cimino L, Persico M, Demelia L, Rumi M, Spinzi G, et al. Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study. Journal of Hepatology 2005;42(2):200-1.
Rahman 2007a {published data only}
  • Rahman F, Schuchmann M, Lohr HF, Link R, Buggisch P, Fuchs M, et al. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotype 1. Hepatology 2007;46(4 Suppl 1):826A.
Rahman 2007b {published data only}
  • Rahman F, Schuchmann M, Lohr HF, Link R, Buggisch P, Fuchs M, et al. Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3. Hepatology 2007;46(4 Suppl 1):826A.
Roffi 2008 {published data only}
  • Roffi L, Colloredo G, Del Poggio P, Fornaciari G, Castagnetti E, Ceriani R, et al. Efficacy and safety of low doses of interferon (IFN) alfa-2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]. Hepatology 2004;40(4 Suppl 1):322A.
  • Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, et al. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antiviral Therapy 2008;13(5):663-73.
Scotto 2005 {published data only}
  • Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. New Microbiologica 2005;28:23-9.
Shobokshi 2003 {published data only}
  • Shobokshi A, Serebour FE, Skakni L, Al-Jasser N, Tantawi AO, Sabah A, et al. Combination therapy of peginterferon alfa-2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]. Hepatology 2003;38(4 Suppl 1):636A.
  • Shobokshi O, Serebour F, Skakni L, Tantawi A, Dinish T, Al Quaiz M, et al. Efficacy of pegylated (40kDa) IFN alfa-2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia. Journal of Hepatology 2002;36(Suppl 1):129.
  • Shobokshi O, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin. Saudi Medical Journal 2003;24(Suppl 2):S92-S93.
  • Shobokshi O, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, et al. Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal 2003;24(Suppl 2):S92-S93.
Sjögren 2007 {published data only}
  • Sjogren MH, Sjogren R, Lyons MF, Ryan M, Santoro J, Smith C, et al. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Digestive Diseases and Sciences 2007;52(6):1540-7.
Thakeb 2003 {published data only}
  • Thakeb FIA, Omar MM, El Awady MM, Isshak SY. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients [AASLD abstract]. Hepatology 2003;38(4 Suppl 1):278A.
Tsubota 2005 {published data only}
  • Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. Journal of Medical Virology 2005;75:27-34.
Wakil 2006 {published data only}
  • Wakil RM, Montasser MF, Mansour MA, Salman TA, El-Batanony MH, Helail EH, et al. Peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive Egyptian patients. Journal of Clinical Virology 2006;36:S142-S143.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
ACTG 2005 {published data only}
  • Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine 2004;351(5):451-9.
  • Sherman KE, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005;128(2):313-27.
Ali 2010 {published data only}
  • Ali S, Nazir G, Khan SA, Iram S, Fatima F. Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients. Journal of Ayub Medical College 2010;22:127-30.
APRICOT 2004 {published data only}
  • Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18(13):F21-F25.
  • Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. Journal of Infectious Diseases 2003;188:1498-507.
  • Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine 2004;351(5):438-50.
Asahina 2004 {published data only}
  • Asahina Y, Izumi N, Onuki Y, Ueda K, Nishimura Y, Nakanishi H, et al. Enhanced interferon (IFN)-stimulated gene expression and HCV dynamics in patients treated with pegylated IFN alfa 2b and ribavirin: effect of pharmacokinetic change of IFN and ribavirin. Hepatology 2004;40(4 Suppl 1):338A.
Gromova 2004 {published data only}
  • Gromova NI, Bogomolov BP. Comparative efficacy of combined treatment with Intron a and Pegintron in combination with ribavirin in patients with chronic hepatitis C. Terapevticheskii Arkhiv 2004;76(2):31-5.
Laguno 2004 {published data only}
  • Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18(13):F27-F36.
RIBAVIC 2004 {published data only}
  • Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004;292(23):2839-48.
  • Lunel F, Pivert A, Payan C. Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (RIBAVIC). Journal of Hepatology 2004;40(Suppl 1):144-5.
  • Pol S, Carrat F, Bani-Sadr F, Rosenthal E, Lunel F, Morand P, et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected [AASLD abstract]. Hepatology 2004;40(4):315A.
  • Pol S, Carrat F, Bani-Sadr F, Rosenthal E, Lunel F, Morand P, et al. Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for naive HCV-HIV co-infected patients. Journal of Hepatology 2005;42(Suppl 2):10-1.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. Additional references
Adeel 2009
Aljumah 2013
Awad 2010
Bailon 2001
  • Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis. Bioconjugate Chemistry 2001;12(2):195-202.
Bangalore 2008
Benvegnu 2001
Bradburn 2006
Brok 2008
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology 2008;61(8):763-9.
Brok 2009
  • Brok J, Thorlund K, Gluud C, Wetterslev J. Apparently conclusive meta-analyses may be inconclusive—trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses. International Journal of Epidemiology 2009;38(1):287-98. [DOI: 10.1093/ije/dyn188]
Brok 2009a
Chan 2013
  • Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Clinical Research Ed.) 2013;8:346:e7586.
Chander 2002
Constant 2005
  • Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. Journal of Clinical Psychiatry 2005;66:105-23.
CTU 2011
  • Copenhagen Trial Unit. TSA—Trial Sequential Analysis. ctu.dk/tsa/ 2011 (accessed 28 May 2013).
Davis 1999
  • Davis GL. Hepatitis C virus genotypes and quasispecies. American Journal of Medicine 1999;107(6B):S21-S26.
DeMets 1987
DerSimonian 1986
Dhillon 2010
  • Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH. Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C. Digestive Diseases and Sciences 2010;55:1785-90.
EASL 2012
Fattovich 2002
  • Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. American Journal of Gastroenterology 2002;97(11):288-95.
    Direct Link:
Foster 2004
Ghany 2009
Glue 2000
Gluud 2007
Gluud 2013
  • Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al. Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2013, Issue 12. Art. No.: LIVER.
Gurusamy 2013
  • Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, et al. Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?. PLoS ONE 2013;8(12):e83313.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed) 2008;336:924-6.
Hadziyannis 2004
  • Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose. Annals of Internal Medicine 2004;140:346–55.
Hauser 2014
  • Hauser G, Awad T, Thorlund K, Štimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C (Review). Cochrane Database of Systematic Reviews 2014, Issue 2.
Higgins 2002
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
Hirofumi 2009
Hodgson 2003
  • Hodgson HJF. Viral hepatitis—clinical aspects. In: Warrell DA, Cox TM, Firth JD, Benz EJ Jr editor(s). Oxford Textbook of Medicine. 4th Edition. Oxford/ New York: Oxford University Press, 2003.
Hollis 1999
ICH-GCP 1997
  • International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR & ICH Guidelines. Vol. 1, PA 19063-2043, USA: Barnett International/PAREXEL, 1997.
Khuroo 2004
Kjaergard 2001
Koretz 2013
Krleza-Jeric 2005
  • Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement. BMJ (Clinical Research Ed) 2005;330(7497):956-8.
Kumar 2002
  • Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, et al. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C. American Journal of Gastroenterology 2002;97:2432-40.
    Direct Link:
Lim 2010
Lundh 2012
Moher 1998
  • Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
Moher 2012
  • Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. International Journal of Surgery 2012;10:28-55.
Myers 2002
  • Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD000370]
OPTN 2008
  • United Network for Organ Sharing. Chapter IV; Liver and Intestine Transplantation in the United States, 1998-2007. optn.transplant.hrsa.gov/ar2008/chapter_iv_AR_cd.htm?cp=5 (accessed 27 May 2013).
Penin 2004
  • Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky J. Structural biology of hepatitis C virus. Hepatology 2004; Vol. 39, issue 1:5-19. [DOI: 10.1002/hep.20032]
Raison 2005
Reddy 2001
RevMan 2012 [Computer program]
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Roomer 2010
  • Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Journal of Hepatology 2010;53:455-9.
Rosenberg 2001
Royle 2003
  • Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591-603.
Rücker 2008
Savovic 2012
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Health Technology Assessment 2012;16(35):1-82.
Savovic 2012a
  • Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Annals of Internal Medicine 2012;157(6):429-38.
Schulz 1995
  • Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
Seeff 2002
  • Seeff LB, Hoofnagle JH. National institutes of health consensus development conference: management of hepatitis C: 2002. Hepatology 2002; Vol. 36, issue 5 Suppl 1:S1-S2. [DOI: 10.1002/hep.1840360702]
Seeff 2009
Shepherd 2005
  • Shepherd J, Brodin H, Kan FT, Cave CB, Waugh NR, Price A, et al. Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. International Journal of Technology Assessment in Health Care 2005;21(1):47-54.
Siebert 2005
  • Siebert U, Sroczynski G, German Hepatitis C Model GEHMO Group, HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. International Journal of Technology Assessment in Health Care 2005;21(1):55-65.
Slavenburg 2010
  • Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Digestive Diseases and Sciences 2010;55:579-85.
Soza 2002
Sulkowski 2004
Sulkowski 2011
  • Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nature Reviews. Gastroenterology & Hepatology 2011;8:212-23.
Thorlund 2009
Thorlund 2010
  • Thorlund K, Anema A, Mills E. Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology 2010;2:57-66.
Thorlund 2011
  • Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. User manual forTrial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed 23 April 2013).
van Regenmortel 2000
  • van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. Virus Taxonomy: The Classification and Nomenclature of Viruses. The Seventh Report of the International Committee on Taxonomy of Viruses. San Diego: Academic Press, 2000:599-621.
Wetterslev 2008
  • Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology 2008;61(1):64-75.
Wetterslev 2009
WHO 1999
WHO 2009
  • WHO. International Clinical Trials Registry Platform (ICTRP). www.who.int/ictrp/en/ (accessed 27 May 2013).
Wood 2008
  • Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601-5.
Zaman 2003